Grifols, a CataloniaBio & HealthTech member, has announced the start of production of its anti-SARS-CoV-2 hyperimmune immunoglobulin with specific antibodies using the plasma of people who have overcome the disease. 

Grifols' anti-SARS-CoV-2 immunoglobulin is being produced in its Clayton (US) facility as part of a collaboration agreement with US government, the Food and Drug Administration (FDA), the National Institutes of Health (NIH), among other healthcare agencies. The company is also moving forward to establish collaborations in Europe.

The first doses will be available in July 2020 as part of a clinical trial in Spain to assess the effectiveness of the theraphy.

More information

Photo: Raimon Grífols and Víctor Grífols Deu, CEOs of Grifols

You also may be interested in:

• Grifols completes development of a high sensitivity diagnostic test for Covid-19
• Grifols announces collaboration with US Government for a treatment against Covid-19